Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 7venetoclax 6Azacitidine 6fludarabine 5Cytarabine 4Blood Specimen Collection 4daratumumab 3Lenalidomide 3Daunorubicin 3tislelizumab 2fludarabine phosphate 2Rituximab 2Liquid Biopsy 2Idarubicin 2Gemtuzumab 2Capecitabine 2Busulfan 2trastuzumab deruxtecan 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sugemalimab 1sacituzumab govitecan 1relugolix 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm, Residual × Transplantation, Autologous × Clear all
NCT06463717 2024-06-24

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

First Affiliated Hospital of Zhejiang University

Recruiting
210 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡